| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | RSS | TABLE OF CONTENTS |
|
|
|
||||||||
|
||||||||||
Clinical Investigations |
1 Department of Nuclear Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
2 Department of Neurology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
In Parkinson’s disease (PD), both neuropathologic and biochemical studies suggest that serotonin (5-hydroxytryptamine [5-HT]) neurons are affected by the disease process. The integrity of 5-HT transporters was assessed in PD patients with SPECT using 2ß-carbomethoxy-3ß-(4-123I-iodophenyl)tropane (123I-ß-CIT), which binds with high affinity to both dopamine (DA) and 5-HT transporters. Methods: Forty-five PD patients at relatively early stages (mean Hoehn-Yahr stage, 2.0 ± 0.7; range, 1–3) and 7 age-matched healthy control subjects had 15 scans over a 24-h period after injection of 123I-ß-CIT using a 3-head SPECT system. In the midbrain, the 5-HT transporter parameter k3/k4 was estimated by 3 noninvasive methods: pseudoequilibrium ratio (RPE) method, area ratio (RA) method, and a modified graphic method that derives the ratio of ligand distribution volumes (RV). Striatal V3'', the DA transporter parameter that is equivalent to k3/k4, was measured using the images acquired at 24 h after tracer injection. All measures were derived using the cerebellum as the reference region. Results: In control subjects, the 123I-ß-CIT activity in the midbrain reached a peak at 91 ± 21 min after injection and then washed out at a slow rate (1.1%/h ± 0.5%/h). The peak specific uptake in the midbrain occurred at 315 ± 46 min. In PD patients, the temporal patterns of the midbrain and cerebellar activity were not significantly different from those in control subjects. None of midbrain RPE, RA, and RV was significantly different between control subjects and PD patients, whereas striatal V3'' was bilaterally reduced in all patients, being 32% lower than that of the control subjects (P = 0.002). In PD patients, none of the midbrain outcome measures was significantly correlated with either striatal V3'' or motor or nonmotor symptom ratings, including the Hoehn-Yahr stage and the Unified Parkinson’s Disease Rating Scale scores. When the studies of 7 PD patients with depression were analyzed separately, none of the midbrain outcome measures in these patients either was different significantly from control values or correlated with the Hamilton Depression Rating Scale score. Conclusion: These results suggest that DA and 5-HT transporters are differentially affected in PD, and 5-HT transporters in the midbrain region may not be affected in relatively early stages of PD. Alternatively, 5-HT transporters in the remaining neurons may be upregulated, thus raising the midbrain 5-HT transporter density to almost normal levels.
Key Words: Parkinson’s disease • midbrain • serotonin transporter • dopamine transporter • 2ß-carbomethoxy-3ß-(4-123I-iodophenyl)tropane • SPECT
This article has been cited by other articles:
|
|
 |
|
  A. B. Newberg, K. Plossl, P. D. Mozley, J. B. Stubbs, N. Wintering, M. Udeshi, A. Alavi, T. Kauppinen, and H. F. Kung Biodistribution and Imaging with 123I-ADAM: A Serotonin Transporter Imaging Agent J. Nucl. Med., May 1, 2004; 45(5): 834 - 841. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Barthel, S. Hesse, and O. Sabri 123I-{beta}-CIT SPECT for Imaging Serotonin Transporters in Parkinson's Disease J. Nucl. Med., May 1, 2004; 45(5): 923 - 924. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | RSS | TABLE OF CONTENTS |
| JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY | THE JOURNAL OF NUCLEAR MEDICINE |
